American Society of Addiction Medicine

This Week in Addiction Medicine from ASAM

American Society of Addiction Medicine

  • Lead: Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols

Lead: Building Multidisciplinary Consensus on Inpatient Xylazine Management through Clinical Protocols

Tuesday 6th May 2025

Explore clinical protocols for managing xylazine exposure in hospitals. Learn about treatment strategies and the role of multidisciplinary teams.
7 minutes
Informative
Educational
Supportive
Hopeful
Engaging

About this podcast

This Week in Addiction Medicine from ASAM
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Rounded Button Dark
Do you want to link to this podcast?
Get the buttons here!

Managing Xylazine Exposure: Protocols and Insights

Episode Overview

  • Multidisciplinary teams develop protocols for managing xylazine exposure.
  • Scheduled clonidine or tizanidine recommended for withdrawal management.
  • Assume xylazine exposure in high-prevalence areas due to lack of testing.
  • Guidelines provided for surgical interventions and wound care.
  • Discharge instructions include referrals to substance use disorder treatment.
"Assume xylazine exposure in areas with high prevalence and limited testing",
Ever wondered how medical experts tackle the chaos caused by substances like xylazine? This episode of 'This Week in Addiction Medicine' dives into the complex world of inpatient xylazine management, offering a peek into how multidisciplinary teams craft clinical protocols to address the challenges posed by this drug. You'll learn about the strategic use of medications like clonidine and tizanidine to manage withdrawal symptoms and the practical advice on wound care and antibiotic usage.
With no FDA-approved tests for xylazine, the team recommends assuming exposure in high-prevalence areas and provides guidelines for surgical interventions and discharge instructions. But that's not all. The episode also covers a fascinating study comparing oral and injectable naltrexone for alcohol use disorder, revealing that patient preference and affordability might just be the deciding factors. Pregnant individuals with opioid use disorder are also spotlighted, highlighting the importance of medication-assisted treatment in improving retention rates.
If chronic pain is your concern, you'll find insights into mindfulness versus cognitive behavioural therapy for managing opioid-treated back pain. And if you're curious about the rise of psilocybin use or the intriguing effects of phenobarbital on opioid withdrawal treatments, this episode has you covered. With a mix of research findings and expert opinions, this episode offers valuable information for anyone interested in addiction medicine.
Tune in to discover how healthcare professionals are navigating these challenges and what it means for patient care.
alcoholfree.com
Published by The Mindful Drinking Company Limited
4 Providence Court, Pynes Hill, Exeter, Devon, EX2 5JL, England
Registered in England and Wales.
Company Number: 1195057. Vat Number: GB320915135.
Registered address as above.
© Copyright 2005-2025 The Mindful Drinking Company Limited.
All Rights Reserved.
alcoholfree.com is a participant in the Amazon Associates Programme, an affiliate advertising programme designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.co.uk. As an Amazon Associate, we earn from qualifying purchases.